We believe the microbiome is an important scientific frontier within this changing environment. azh-biotics® is our platform for turning that science into defined, testable companion products.
Weight loss changes more than weight.
Modern obesity treatment can change appetite, food intake, nutrient exposure, gastrointestinal physiology and eating patterns.
Research into the microbiome is particularly relevant because the gut sits at the intersection of digestion, nutrient processing, microbial metabolism, immune signalling and metabolic health.
A changing treatment environment creates new biological questions — and new opportunities to test microbiome companion strategies.
From hypothesis to evidence.
We do not stop at biological plausibility.
- 1 INSIGHT Identify real needs across the modern weight-loss journey.
- 2 FORMULATION Build defined microbiome and companion concepts around those needs.
- 3 EVIDENCE Test finished products through clinical, preclinical and real-world programmes.
- 4 LEARNING Understand what works, what does not and where the signal is strongest.
- 5 NEXT GENERATION Translate learning into better products and better studies.
The azh-biotics® platform.
The azh-biotics® platform combines defined bacterial strains, strain-level traceability, formulation and stability science, clinical research, preclinical research, real-world evidence and patient insight. The platform is designed to generate multiple products around specific needs and phases of the modern weight-loss journey.
What makes our approach different.
Defined and
traceable
Clearly identified strains and recognised deposit systems support transparency and future research.
Built around
a real use case
The platform is designed around changing needs during modern weight management rather than being retrospectively positioned for the category.
Finished-product evidence
Forte80® has been tested as a finished formulation alongside semaglutide in adults with obesity.[10]
Evidence-led development
The programme incorporates positive, negative and exploratory findings into the next generation of studies and products.
A growing evidence programme.
Azento Health is building evidence across multiple levels: randomized clinical research, real-world patient experience, in vitro and mechanistic research, and future microbiome and biomarker studies.
Forte80® provides the first clinical proof point. Future programmes are designed to test more focused questions around Better Weight Loss and stage-specific companion needs.
One journey. Different biological and practical needs.
Obesity treatment is not one single moment. Patients may need different support before treatment, during dose escalation, throughout active weight loss, in longer-term treatment and during transition. Azento Health is therefore developing a stage-specific pipeline across microbiome support, daily nutrition, hydration, muscle and bone health, metabolic support and maintenance.
Every person is different. Every stage brings different needs.